PLX

#3115
Protalix BioTherapeutics, Inc. Common Stock
2.8300 USD
+1.07%
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
2.7890
2.8450
Jahresspanne
2.5850
3.1900
Tagesänderung
+1.07%
Monatliche Änderung
-3.08%
6 month change
-3.08%
Jahresänderung
-3.08%
Vorheriger Schlusskurs
2.8000
Open
2.8200
Bid
2.8300
Ask
2.8330
Low
2.7890
High
2.8450
Volumen
288
Open full chart

Financials

Overview Finanzbericht Statistics
Quarterly Annual
  • Market Capitalization 221.3771 M
  • Employee 213
  • Founded 1993
  • CEO Dror Bashan
  • Website www.protalix.com
  • Headquarter Delaware, United States
  • FIGI BBG000JW08N5
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
47
Price to sales ratio
2.85

Protalix BioTherapeutics Inc (DE)

Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.

Nachrichten